中国长效针剂治疗精神分裂症的药物经济学系统评价  

Pharmacoeconomic evaluation of long-acting injections for the treatment of schizophrenia in China:A systematic review

作　　者：杨诗雯 樊成 陈途 傅芃 邓雪华 吴文荣 姜淑珍 杨远坚 YANG Shiwen;FAN Cheng;CHEN Tu(Jiangxi Mental Health Center,Jiangxi Clinical Research Center for Mental Disorders,Nanchang 330029,China)

机构地区：[1]江西省精神病院,江西省精神心理疾病临床研究中心,江西南昌330029 [2]江西省卫生健康委员会 [3]咸宁市公共检验检测中心

出　　处：《精神医学杂志》2024年第6期595-600,共6页Journal of Psychiatry

基　　金：江西省卫生健康委员会2024年度科技计划项目(编号:202410547);江西省精神心理疾病临床研究中心项目(编号:2020BCG74002)。

摘　　要：目的对中国抗精神病药长效针剂(LAIs)治疗精神分裂症(SZ)的药物经济学研究进行系统性评估。综合分析LAIs的经济性及其影响因素。方法通过关键词检索、筛选文献后,对文献进行质量评估和药物经济学评价。结果共纳入11篇文献,CHEERS 2022平均符合率为37.99%,6项研究结果支持每月注射1次的棕榈酸帕利哌酮注射液(PP1M)更具有药物经济学优势,4项结果支持注射用利培酮微球(RLAI),1项支持每3月注射1次的棕榈酸帕利哌酮注射液(PP3M)。结论关于中国LAIs治疗SZ的大多数研究均支持PP1M更具有药物经济学优势,表明相比其他LAIs和口服抗精神病药(OA),PP1M为优势治疗方案。Objective To conduct a systematic evaluation of the pharmacoeconomics of long-acting antipsychotic injections(LAIs)for the treatment of schizophrenia(SZ)in China,and to comprehensively analyze the economic efficiency of LAIs and its influencing factors.Methods After searching and screening the literature through keywords,the quality of the literature was assessed and the pharmacoeconomic evaluation was performed.Results A total of 11 articles were included,and the average CHEERS 2022 compliance rate was 37.66%.6 research results supported that a greater pharmacoeconomic benefit for paliperidone palmitate 1-month(PP1M),4 results supported risperidone microspheres for injection(RLAI),and 1 supported paliperidone palmitate 3-month(PP3M).Conclusion Most trials of LAIs in the treatment of SZ in China support that PP1M has a greater pharmacoeconomic advantage,suggesting that PP1M is the superior option compared with other LAIs and oral antipsychotics.

关 键 词：长效针剂 精神分裂症 药物经济学评价 抗精神病药物 

分 类 号：R956[医药卫生—药学]